Cargando…
Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal disease. The treatment is challenging and nowadays a comprehensive approach based not only in pharmacological strategies is necessary. Identification and control of comorbidities, non-pharmacological treatment, prevention and ma...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164236/ https://www.ncbi.nlm.nih.gov/pubmed/30042369 http://dx.doi.org/10.3390/medsci6030059 |
_version_ | 1783359551365447680 |
---|---|
author | Millan-Billi, Paloma Serra, Candela Alonso Leon, Ana Castillo, Diego |
author_facet | Millan-Billi, Paloma Serra, Candela Alonso Leon, Ana Castillo, Diego |
author_sort | Millan-Billi, Paloma |
collection | PubMed |
description | Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal disease. The treatment is challenging and nowadays a comprehensive approach based not only in pharmacological strategies is necessary. Identification and control of comorbidities, non-pharmacological treatment, prevention and management of exacerbations as well as other areas of care (social, psychological) are fundamental for a holistic management of IPF. Gastroesophageal reflux, pulmonary hypertension, obstructive sleep apnea, combined with emphysema, lung cancer and cardiovascular involvement are the main comorbidities associated with IPF. Non-pharmacological treatment includes the use of oxygen in patients with rest or nocturnal hypoxemia and other support therapies such as non-invasive ventilation or even a high-flow nasal cannula to improve dyspnea. In some patients, lung transplant should be considered as this enhances survival. Pulmonary rehabilitation can add benefits in outcomes such control of dyspnea, exercise capacity distance and, overall, improve the quality of life; therefore it should be considered in patients with IPF. Also, multidisciplinary palliative care programs could help with symptom control and psychological support, with the aim of maintaining quality of life during the whole process of the disease. This review intends to provide clear information to help those involved in IPF follow up to improve patients’ daily care. |
format | Online Article Text |
id | pubmed-6164236 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61642362018-10-10 Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis Millan-Billi, Paloma Serra, Candela Alonso Leon, Ana Castillo, Diego Med Sci (Basel) Review Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal disease. The treatment is challenging and nowadays a comprehensive approach based not only in pharmacological strategies is necessary. Identification and control of comorbidities, non-pharmacological treatment, prevention and management of exacerbations as well as other areas of care (social, psychological) are fundamental for a holistic management of IPF. Gastroesophageal reflux, pulmonary hypertension, obstructive sleep apnea, combined with emphysema, lung cancer and cardiovascular involvement are the main comorbidities associated with IPF. Non-pharmacological treatment includes the use of oxygen in patients with rest or nocturnal hypoxemia and other support therapies such as non-invasive ventilation or even a high-flow nasal cannula to improve dyspnea. In some patients, lung transplant should be considered as this enhances survival. Pulmonary rehabilitation can add benefits in outcomes such control of dyspnea, exercise capacity distance and, overall, improve the quality of life; therefore it should be considered in patients with IPF. Also, multidisciplinary palliative care programs could help with symptom control and psychological support, with the aim of maintaining quality of life during the whole process of the disease. This review intends to provide clear information to help those involved in IPF follow up to improve patients’ daily care. MDPI 2018-07-24 /pmc/articles/PMC6164236/ /pubmed/30042369 http://dx.doi.org/10.3390/medsci6030059 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Millan-Billi, Paloma Serra, Candela Alonso Leon, Ana Castillo, Diego Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis |
title | Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis |
title_full | Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis |
title_fullStr | Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis |
title_full_unstemmed | Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis |
title_short | Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis |
title_sort | comorbidities, complications and non-pharmacologic treatment in idiopathic pulmonary fibrosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164236/ https://www.ncbi.nlm.nih.gov/pubmed/30042369 http://dx.doi.org/10.3390/medsci6030059 |
work_keys_str_mv | AT millanbillipaloma comorbiditiescomplicationsandnonpharmacologictreatmentinidiopathicpulmonaryfibrosis AT serracandela comorbiditiescomplicationsandnonpharmacologictreatmentinidiopathicpulmonaryfibrosis AT alonsoleonana comorbiditiescomplicationsandnonpharmacologictreatmentinidiopathicpulmonaryfibrosis AT castillodiego comorbiditiescomplicationsandnonpharmacologictreatmentinidiopathicpulmonaryfibrosis |